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TCT-119
Long-Term Follow-up After Alcohol Septal Ablation for Hypertrophic
Obstructive Cardiomyopathy in Young Adults
Amir-Ali Fassa, Bertrand Cormier, Marie-Claude Morice, Jean-François Piéchaud,
Marie-Christine Malergue, Yves Louvard, Philippe Garot, Thierry Lefevre
Institut Cardiovasculaire Paris Sud, Massy, France
Background: The objective of the study was to assess the long-term safety and efficacy
of alcohol septal ablation (ASA) in young adults.
Methods: Data of 163 consecutive patients who underwent ASA at our institution from
2000 to 2010 were reviewed. Clinical follow-up was obtained at a mean of 3 years
after ASA in patients aged between 18 and 40 years at the time of the procedure.
Results: During the study period, 21 patients (15 males) aged between 18 and 40 years
old (mean age 33.1±5.6, range 18-39 years) underwent ASA. Among them, 76% were
treated with beta-blockers, 33% calcium-channel antagonists and 5% disopyramide.
There were 6 patients (29%) with prior pacemaker, 1 patient (5%) with history of
sudden death and prior implantable cardioverter-defibrillator (ICD) and 1 patient (5%)
with prior myectomy. At baseline, mean New York Heart Association (NYHA)
functional class was 2.4±0.5. Mean left ventricular outflow tract (LVOT) peak gradient
and septal thickness were 89±37mmHg and 24.9±5.1 mm, respectively. All procedures
were performed with myocardial contrast echocardiography guidance. During ASA,
2.2±0.7ml of absolute alcohol was injected in 1.4±0.5 septal perforators. Final
procedural LVOT peak gradient was 20±16mmHg. Procedural success (defined as
immediate LVOT peak gradient reduction >50%) was achieved in 20 patients (95%).
There were no major complications. One patient (5%) required a temporary pacemaker
for second-degree atrioventricular block. Mean peak CK was 934±468 IU/L. At a mean
follow-up of 3.0±2.0 years after the procedure (range 0.3-8.4), repeat ASA was
performed in two patients (10%) and a new ICD was needed in 1 patient (5%), while
there were no fatalities reported. Mean NYHA class was improved to 1.6±0.7.
Conclusion: ASA in young patients appears to be safe and effective. Immediate success
is achieved in a large majority of patients and procedural complication rates are low.
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Mid-Term Outcomes Following Transcatheter Aortic Valve Replacement with
Both Edwards SAPIEN™ and Medtronic CoreValve ReValving System®
Devices According to VARC Definitions: the Milan Experience
Gill Louise Buchanan1, Alaide Chieffo1, Matteo Montorfano1, Francesco Maisano3,
Azeem Latib1, 2, Cosmo Godino1, 2, Micaela Cioni3, Mauro Carlino1, Maria A
Gullace1, Remo D Covello5, Annalisa Franco5, Chiara Gerli5, Antonio Grimaldi3,
Giovanni La Canna3, Pietro Spagnola4, Ottavio Alfieri3, Antonio Colombo1, 2
1Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy;
2EMO-GVM Cento Cuore, Columbus, Milan, Italy; 3Cardiac Surgery Unit, San
Raffaele Scientific Institute, Milan, Italy; 4Radiology Unit, San Raffaele Scientific
Institute, Milan, Italy; 5Department of Anaesthesia and Intensive Care, San Raffaele
Scientific Institute, Milan, Italy
Background: Our aim was to assess the outcomes of transcatheter aortic valve
replacement (TAVR) according to the Valve Academic Research Consortium (VARC)
definitions at 30 days and 1 year.
Methods: All consecutive patients from our single-center prospective registry with
aortic stenosis treated with TAVR from November 2007 to April 2011, via the
transfemoral (TF), transapical (TAp), transaxillary (TAx) or transaortic (TAo) routes
utilizing either the Edwards SAPIEN™ valve (ESV) (Edwards Lifesciences, Irvine,
California) or Medtronic CoreValve ReValving System® (MCV) (Medtronic,
Minneapolis, Minnesota) were analyzed. The study endpoints were defined according
to the VARC definitions, retrospectively adjudicated.
Results: A total of 305 patients were included: mean age was 79.4±7.3 years and
Logistic EuroSCORE 24.2±17.0%. Median clinical follow-up length was 279 (IQR
51-485) days. The most frequent access was TF (81.6%) followed by TAx (10.2%),
TAp (7.2%) and TAo (1.0%). ESV was implanted in 60.7% of the patients. Thirty-day
mortality was 4.7%, with a myocardial infarction rate of 1.3% and stroke of 1.0%. At
multivariate analysis, body mass index and logistic EuroSCORE were significantly
associated with an increased risk of 30-day mortality. Life-threatening bleeding
occurred in 25.9% of the patients and 15.7% had major vascular complications.
According to access site or type of valve, there was no difference in device success
(92.5% overall), combined safety endpoint at 30 days (61.8%) or combined efficacy
endpoint (72.0%) at one year follow-up. Conversely, there was a significantly higher
occurrence of conduction disturbances and/or arrhythmia (10.1% vs. 23.1%; p=0.006)
as well as need of pacemaker (6.3% vs. 28.6%; p<0.001) with MCV as compared to
ESV.
Conclusion: Routine TAVR using both ESV and MCV via a range of access appears
feasible, with good overall device success and outcomes.
TCT-121
Late Structural Integrity of Balloon Expandable Stents used for Transcatheter
Aortic Valve Replacement : Assessment by Multi-detector Computerized
Tomography
Alex Bruce Willson, Webb G John, Gurvitch Ronen, Stefan Toggweiler, Binder
Ronald, Wood David, Mark Madden, Cameron Hague, Jonathon Leipsic
Interventional Cardiology Research, St Pauls Hospital Vancouver, Vancouver,
Canada
Background: Late biosprosthetic valve failure most commonly results from leaflet
degeneration but may also be caused by gross deformity of the valve frame. Late
structural integrity of the balloon expandable stents used in transcatheter aortic valve
replacement (TAVR) is ill defined. We evaluated stent circularity, expansion and
evidence of frame fracture late post implantation using multidetector computerized
tomography(MDCT).
Methods: Subjects greater than 1 year post implantation of a balloon expandable aortic
valve underwent MDCT. Geometry of the stent frame was assessed for circularity,
minimum (Dmin) and maximum (Dmax) external diameter and expansion ratio at three
levels : inflow, mid and outflow. Circularity was defined as an eccentricity index (EI)
of less than 0.1 (EI = 1-Dmin/Dmax) and expansion ratio as a percentage of the
measured cross sectional stent area divided by the expected area for a fully expanded
valve.
Results: 48 patients underwent MDCT at an average 2.5 years (1.0-4.0yrs) post
implantation including 34 Edward SAPIEN valves, 7 SAPIEN XT valves and 7 Cribier
Edwards(CE) valves. 143 of 144 (99%) analyzed segments of the 48 valves were
circular. The was no difference in eccentricity between valve type (CE : EI 1.8±1.1%,
SAPIEN: EI 2.7±2.2%, XT 2.1±2.2%, p=0.71) or from the inflow to outflow aspect of
the stent (p=0.54). The mean external diameter of the 23 and 26 mm valves was
23.4±0.9mm and 25.9±0.9mm respectively. The average expansion ratio was
104.1±7.4% with a significant increase from the inflow to outflow frame level
(100.5±7.6%vs 108.1±6.9%, p<0.001). The was no difference in ER between valve
type (CE 101.6±7.2%, SAPIEN 104.7±7.2%, XT 103.3±8.4%, p=0.48 ).There were
no cases of stent fracture.
Conclusion: Balloon expandable aortic valves have excellent rates of circularity and
maintain full expansion without stent fracture late following implantation, thus
supporting long term valve durability.
TCT-122
Short- and Long-Term Safety and Effectiveness of Transcatheter Aortic Valve
Implantation in a Failing Surgical Aortic Bioprosthesis
Ralf Mueller1, Robert Bauernschmitt2, Gerhard Schuler3
1HELIOS Heart Center, Siegburg, Germany; 2German Heart Center Munich,
Munich, Germany; 3University of Leipzig Heart Center, Leipzig, Germany
Background: The viability of transcatheter aortic valve implantation (TAVI) in patients
with a failing previously-implanted surgical aortic bioprosthesis has been reported,
mostly from single centers. We present results from a multicenter feasibility study in
patients followed for one year after TAVI implant.
Methods: The RE-DO study evaluated 18 subjects implanted with the 18Fr CoreValve
TAVI prosthesis (Medtronic, Irvine, Calif.) in a failing surgical aortic bioprosthesis at
three centers in Germany. Subject inclusion requirements included > 75 years old and
either surgical risk with logistic EuroSCORE > 15% or >1 high-risk co-morbidity.
Results: Implanted subjects were 79 ± 4 years old, 67% male, 78% NYHA class III/IV,
logistic EuroSCORE 34 ± 14, and had failed surgical bioprostheses from six
manufacturers. The procedure was considered successful by the implanting physicians
in 89% (16/18) of cases. One subject was converted to surgery during the procedure
and another was successfully implanted after a second attempt. Mortality at 30 days
and one year were 11% (2/18) and 28% (5/18). Two cardiac deaths occurred, including
one within 30 days. Two subjects had strokes, both within 30 days. After 30 days and
12 months, 86% and 73% of subjects improved at least one NYHA class and the
remainder had no change. Aortic regurgitation was grade 0 or 1 (none/mild) in 86% of
patients at 30 days and in 100% of patients at 1 year. Aortic valve area and mean
gradient showed a significant improvement at 30 days that was sustained through at
least one year. A moderate improvement was observed in LVEF.
Conclusion: Most patients with a failing surgical bioprosthesis were successfully
implanted with a TAVI prosthesis in this multicenter feasibility study. Outcomes at 30
days were within expectations for this very high-risk subgroup and improvements were
sustained through twelve months.
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